2025 Q4 -tulosraportti
22 päivää sitten
‧44 min
Tarjoustasot
Nasdaq Stockholm
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 1 000 | - | - | ||
| 819 | - | - | ||
| 100 | - | - | ||
| 10 214 | - | - | ||
| 35 000 | - | - |
Ylin
0,199VWAP
Alin
0,19VaihtoMäärä
0,2 882 914
VWAP
Ylin
0,199Alin
0,19VaihtoMäärä
0,2 882 914
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 893 895 | 893 895 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 893 895 | 893 895 | 0 | 0 |
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2027 Q1 -tulosraportti 29.4.2027 |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 12.2. | ||
2025 Q3 -tulosraportti 23.10.2025 | ||
2025 Q2 -tulosraportti 10.7.2025 | ||
2025 Q1 -tulosraportti 24.4.2025 | ||
2024 Q4 -tulosraportti 22.1.2025 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·1 t sitten · MuokattuIt is of course silly that TO 14 is priced at 0.20 SEK instead of 0.18 SEK. But I assume that most shareholders in this stock are interested in the company having as much cash as possible. So let's bite the bullet, not be petty, and pay the 5 % -10 % more than the current price of the share and subscribe fully to the TO. It can become much more expensive for us shareholders in the long run if we don't do it - and it then forces the company into a rights issue afterwards, which is always incredibly expensive for the current shareholders. Not to mention if the company were to end up in bankruptcy because we were too stingy to support it here and now, because a share cost one Swedish öre too much. It can be very short-sighted to decline participation. So do as I do, if you don't want to invest additional money in the stock. I do exactly as I usually do and always recommend: Sell the necessary number of ordinary shares - even if I sell at a loss - so I get the money I need to fully exercise my TOs. It may seem like a big loss to sell, but it isn't, when you simultaneously get new shares, but just slightly fewer than you sell. The real loss is only the half or whole Swedish öre you pay extra for each of the new shares compared to today's price. In return, you help secure the company's future development - and that will probably also benefit us shareholders in the long run. There is nothing worse in the stock market than when a company is forced into a rights issue (apart from bankruptcy, of course.) I myself buy 650.000 new shares on my TO 14. That will then cost me an additional expense of perhaps 6-7.000 SEK. It's not worse than that!
·1 päivä sittenThat something "extraordinary" is needed to save To 14 is quite clear to everyone. So also with the company management. What the next news contains for goodies is the question, which probably must be something truly impactful.
·2 t sittenEarlier (approx. a year ago) it was announced on a conference call that company(ies) was/were in the process of due diligence. It would be nice if one could get an update on how many potential buyers have left the table after due diligence and if any new ones have joined.
·28.2.Yes, everyone has probably read the press release https://alligatorbioscience.se/en/mfn_news/exercise-price-determined-for-the-exercise-of-warrants-series-to-14-in-alligator-bioscience-ab/ so the question is whether management will present a "letter of intent" or similar regarding a partnership before March 17 to save the 49 MSEK issue, as the share price is now below the subscription price (0.20), perhaps even before March 5. Or support buying. What do you think?
1 päivä sitten · Muokattu1 päivä sitten · MuokattuI'll correct it. They estimated the bid would have been <20 MUSD. Naturally, long-term royalties and revenue opportunities would be lost at an a low price. But what if that's the only option to get funding for further negotiations on mitazalimab? How do you see it? I recommend reading Redeye's review. https://www.redeye.se/research/1149659/alligator-bioscience-q4-review-deal-or-no-deal
24.2.24.2.this can jump 500% any day if they just find a partner25.2.25.2.maybe this time is different?
·20.2.Just a thought Could one imagine that avanza is about to buy itself into a position of power in here, There to eliminate management and the board and find some competent consultants, with the aim of finding A potential interested buyer for this company, which is about to dilute itself to practically 0 Acquisition perhaps at level 0.5, Does anyone have thoughts on this ?…….
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
22 päivää sitten
‧44 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·1 t sitten · MuokattuIt is of course silly that TO 14 is priced at 0.20 SEK instead of 0.18 SEK. But I assume that most shareholders in this stock are interested in the company having as much cash as possible. So let's bite the bullet, not be petty, and pay the 5 % -10 % more than the current price of the share and subscribe fully to the TO. It can become much more expensive for us shareholders in the long run if we don't do it - and it then forces the company into a rights issue afterwards, which is always incredibly expensive for the current shareholders. Not to mention if the company were to end up in bankruptcy because we were too stingy to support it here and now, because a share cost one Swedish öre too much. It can be very short-sighted to decline participation. So do as I do, if you don't want to invest additional money in the stock. I do exactly as I usually do and always recommend: Sell the necessary number of ordinary shares - even if I sell at a loss - so I get the money I need to fully exercise my TOs. It may seem like a big loss to sell, but it isn't, when you simultaneously get new shares, but just slightly fewer than you sell. The real loss is only the half or whole Swedish öre you pay extra for each of the new shares compared to today's price. In return, you help secure the company's future development - and that will probably also benefit us shareholders in the long run. There is nothing worse in the stock market than when a company is forced into a rights issue (apart from bankruptcy, of course.) I myself buy 650.000 new shares on my TO 14. That will then cost me an additional expense of perhaps 6-7.000 SEK. It's not worse than that!
- ·1 päivä sittenThat something "extraordinary" is needed to save To 14 is quite clear to everyone. So also with the company management. What the next news contains for goodies is the question, which probably must be something truly impactful.·2 t sittenEarlier (approx. a year ago) it was announced on a conference call that company(ies) was/were in the process of due diligence. It would be nice if one could get an update on how many potential buyers have left the table after due diligence and if any new ones have joined.
- ·28.2.Yes, everyone has probably read the press release https://alligatorbioscience.se/en/mfn_news/exercise-price-determined-for-the-exercise-of-warrants-series-to-14-in-alligator-bioscience-ab/ so the question is whether management will present a "letter of intent" or similar regarding a partnership before March 17 to save the 49 MSEK issue, as the share price is now below the subscription price (0.20), perhaps even before March 5. Or support buying. What do you think?1 päivä sitten · Muokattu1 päivä sitten · MuokattuI'll correct it. They estimated the bid would have been <20 MUSD. Naturally, long-term royalties and revenue opportunities would be lost at an a low price. But what if that's the only option to get funding for further negotiations on mitazalimab? How do you see it? I recommend reading Redeye's review. https://www.redeye.se/research/1149659/alligator-bioscience-q4-review-deal-or-no-deal
- 24.2.24.2.this can jump 500% any day if they just find a partner25.2.25.2.maybe this time is different?
- ·20.2.Just a thought Could one imagine that avanza is about to buy itself into a position of power in here, There to eliminate management and the board and find some competent consultants, with the aim of finding A potential interested buyer for this company, which is about to dilute itself to practically 0 Acquisition perhaps at level 0.5, Does anyone have thoughts on this ?…….
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Stockholm
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 1 000 | - | - | ||
| 819 | - | - | ||
| 100 | - | - | ||
| 10 214 | - | - | ||
| 35 000 | - | - |
Ylin
0,199VWAP
Alin
0,19VaihtoMäärä
0,2 882 914
VWAP
Ylin
0,199Alin
0,19VaihtoMäärä
0,2 882 914
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 893 895 | 893 895 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 893 895 | 893 895 | 0 | 0 |
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2027 Q1 -tulosraportti 29.4.2027 |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 12.2. | ||
2025 Q3 -tulosraportti 23.10.2025 | ||
2025 Q2 -tulosraportti 10.7.2025 | ||
2025 Q1 -tulosraportti 24.4.2025 | ||
2024 Q4 -tulosraportti 22.1.2025 |
2025 Q4 -tulosraportti
22 päivää sitten
‧44 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2027 Q1 -tulosraportti 29.4.2027 |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 12.2. | ||
2025 Q3 -tulosraportti 23.10.2025 | ||
2025 Q2 -tulosraportti 10.7.2025 | ||
2025 Q1 -tulosraportti 24.4.2025 | ||
2024 Q4 -tulosraportti 22.1.2025 |
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·1 t sitten · MuokattuIt is of course silly that TO 14 is priced at 0.20 SEK instead of 0.18 SEK. But I assume that most shareholders in this stock are interested in the company having as much cash as possible. So let's bite the bullet, not be petty, and pay the 5 % -10 % more than the current price of the share and subscribe fully to the TO. It can become much more expensive for us shareholders in the long run if we don't do it - and it then forces the company into a rights issue afterwards, which is always incredibly expensive for the current shareholders. Not to mention if the company were to end up in bankruptcy because we were too stingy to support it here and now, because a share cost one Swedish öre too much. It can be very short-sighted to decline participation. So do as I do, if you don't want to invest additional money in the stock. I do exactly as I usually do and always recommend: Sell the necessary number of ordinary shares - even if I sell at a loss - so I get the money I need to fully exercise my TOs. It may seem like a big loss to sell, but it isn't, when you simultaneously get new shares, but just slightly fewer than you sell. The real loss is only the half or whole Swedish öre you pay extra for each of the new shares compared to today's price. In return, you help secure the company's future development - and that will probably also benefit us shareholders in the long run. There is nothing worse in the stock market than when a company is forced into a rights issue (apart from bankruptcy, of course.) I myself buy 650.000 new shares on my TO 14. That will then cost me an additional expense of perhaps 6-7.000 SEK. It's not worse than that!
- ·1 päivä sittenThat something "extraordinary" is needed to save To 14 is quite clear to everyone. So also with the company management. What the next news contains for goodies is the question, which probably must be something truly impactful.·2 t sittenEarlier (approx. a year ago) it was announced on a conference call that company(ies) was/were in the process of due diligence. It would be nice if one could get an update on how many potential buyers have left the table after due diligence and if any new ones have joined.
- ·28.2.Yes, everyone has probably read the press release https://alligatorbioscience.se/en/mfn_news/exercise-price-determined-for-the-exercise-of-warrants-series-to-14-in-alligator-bioscience-ab/ so the question is whether management will present a "letter of intent" or similar regarding a partnership before March 17 to save the 49 MSEK issue, as the share price is now below the subscription price (0.20), perhaps even before March 5. Or support buying. What do you think?1 päivä sitten · Muokattu1 päivä sitten · MuokattuI'll correct it. They estimated the bid would have been <20 MUSD. Naturally, long-term royalties and revenue opportunities would be lost at an a low price. But what if that's the only option to get funding for further negotiations on mitazalimab? How do you see it? I recommend reading Redeye's review. https://www.redeye.se/research/1149659/alligator-bioscience-q4-review-deal-or-no-deal
- 24.2.24.2.this can jump 500% any day if they just find a partner25.2.25.2.maybe this time is different?
- ·20.2.Just a thought Could one imagine that avanza is about to buy itself into a position of power in here, There to eliminate management and the board and find some competent consultants, with the aim of finding A potential interested buyer for this company, which is about to dilute itself to practically 0 Acquisition perhaps at level 0.5, Does anyone have thoughts on this ?…….
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Stockholm
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 1 000 | - | - | ||
| 819 | - | - | ||
| 100 | - | - | ||
| 10 214 | - | - | ||
| 35 000 | - | - |
Ylin
0,199VWAP
Alin
0,19VaihtoMäärä
0,2 882 914
VWAP
Ylin
0,199Alin
0,19VaihtoMäärä
0,2 882 914
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 893 895 | 893 895 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 893 895 | 893 895 | 0 | 0 |